2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose: The objective of this study was to analyze the safety and efficacy of definitive chemoradiotherapy and salvage chemotherapy in pancreatic cancer (PC) patients with isolated locoregional recurrence after radical resection and assess the factors associated with tumor response.

          Patients and methods: A retrospective study of isolated locoregional recurrent PC patients who were treated with definitive chemoradiotherapy and salvage chemotherapy at our institution between 2012 and 2017 was conducted. Medium dose of 56.0 Gy (range: 54.0 Gy - 60.2 Gy) in 1.8 Gy to 2.15 Gy daily fractions was prescribed to the PTV-G and 50.4 Gy was prescribed to the PTV-C. Patients received chemotherapy before, at the same time with or after radiotherapy. The overall survival (OS) and freedom from locoregional progression (FFLP) rates were estimated by the Kaplan–Meier method, and the log-rank test was performed to compare survival curves. The Cox regression was used to identify factors affecting response to treatment and survival.

          Results: Thirty-one patients were included. The median interval from the resection of primary PC to the diagnosis of the locoregional recurrence (DFI) was 7.4 months (range 0.2–44.6). Within a median follow-up from the start of radiotherapy (RT) of 31.7 months (95% CI: 20.0–43.5 months), the medium OS and FFLP rates from the start of RT were 23.6 and 12.0 months, respectively. DFI >6 months was shown to be a significant factor associated with favorable OS. Acute and late toxicity of grade 3 occurred in 3 patients (9.7%) and 1 patient (3.2%) respectively. No grade 4 toxicity or higher occurred.

          Conclusions: This single-institution retrospective analysis identified definitive chemoradiotherapy and salvage chemotherapy to be a feasible and tolerable treatment strategy for patients with isolated locoregional recurrence after radical resection of primary PC.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: not found
          • Article: not found

          Oligometastases.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Oligometastases revisited.

            We previously proposed a clinical state of metastasis termed 'oligometastases' that refers to restricted tumor metastatic capacity. The implication of this concept is that local cancer treatments are curative in a proportion of patients with metastases. Here we review clinical and laboratory data that support the hypothesis that oligometastasis is a distinct clinical entity. Investigations of the prevalence, mechanism of occurrence, and position in the metastatic cascade, as well as the determination of molecular markers to distinguish oligometastatic from polymetastatic disease, are ongoing.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Radiation dose-volume effects in the stomach and small bowel.

              Published data suggest that the risk of moderately severe (>or=Grade 3) radiation-induced acute small-bowel toxicity can be predicted with a threshold model whereby for a given dose level, D, if the volume receiving that dose or greater (VD) exceeds a threshold quantity, the risk of toxicity escalates. Estimates of VD depend on the means of structure segmenting (e.g., V15 = 120 cc if individual bowel loops are outlined or V45 = 195 cc if entire peritoneal potential space of bowel is outlined). A similar predictive model of acute toxicity is not available for stomach. Late small-bowel/stomach toxicity is likely related to maximum dose and/or volume threshold parameters qualitatively similar to those related to acute toxicity risk. Concurrent chemotherapy has been associated with a higher risk of acute toxicity, and a history of abdominal surgery has been associated with a higher risk of late toxicity. Copyright 2010 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                Cancer Manag Res
                Cancer Manag Res
                CMAR
                cancmanres
                Cancer Management and Research
                Dove
                1179-1322
                31 May 2019
                2019
                : 11
                : 5065-5073
                Affiliations
                [1 ]Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, People’s Republic of China
                [2 ]Department of Oncology, Shanghai Medical College , Shanghai, People’s Republic of China
                [3 ]Clinical Statistic Center, Shanghai Cancer Center and Shanghai Medical College, Fudan University , Shanghai, People’s Republic of China
                [4 ]Department of Radiation Oncology, Zhebei Mingzhou Hospital , Huzhou City, Zhejiang Province, People’s Republic of China
                [5 ]Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center , Shanghai, People’s Republic of China
                Author notes
                Correspondence: Jiandong ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center , No. 270 Dong An Road, Shanghai200032, People’s Republic of ChinaTel/Fax +86 216 417 5590Email neilzhaojiandong@ 123456yahoo.com
                Article
                202543
                10.2147/CMAR.S202543
                6549434
                31213918
                df66c254-cb60-4635-b6c2-9c36975b26a8
                © 2019 Shi et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 22 January 2019
                : 16 May 2019
                Page count
                Figures: 1, Tables: 5, References: 37, Pages: 9
                Categories
                Original Research

                Oncology & Radiotherapy
                pancreatic cancer,isolated locoregional recurrence,locoregional oligo-recurrence,chemoradiotherapy,radiotherapy

                Comments

                Comment on this article